The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

Aerocrine passes regulatory milestone in Japan

Thursday, 04 April 2013
Aerocrine AB (OMX Nordic Exchange: AERO) announces that the Japanese authority (PMDA) has approved its FeNO (fractional exhaled nitric oxide)-measuring device, NIOX MINO ® from 2008 as a tool for assessing patients with airway inflammation such as asthma.

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA), decided on 28 of March 2013, after a thorough review, to grant the 2008 version of the NIOX MINO® marketing approval in Japan the company writes in a press release.

"We look upon this approval as a positive regulatory milestone. We are very proud of being the first company to receive approval for the FeNO-method in Japan," said Tobias Bergenblad, Commercial Director Aerocrine for Asia.
Asthma is a fast growing health care problem, which is caused by a chronic inflammation in the airways.
By Scancomark.com Team

We welcome your contribution. Did you find anything wrong with this article? Do you want to contribute to our news network? Do have a news tip or assist us with a correction